GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerpio Pharmaceuticals Inc (NAS:ARPO) » Definitions » Other Current Assets

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Other Current Assets : $0.58 Mil (As of Jun. 2021)


View and export this data going back to 2017. Start your Free Trial

What is Aerpio Pharmaceuticals Other Current Assets?

Aerpio Pharmaceuticals's other current assets for the quarter that ended in Jun. 2021 was $0.58 Mil.

Aerpio Pharmaceuticals's quarterly other current assets declined from Dec. 2020 ($2.11 Mil) to Mar. 2021 ($1.99 Mil) and declined from Mar. 2021 ($1.99 Mil) to Jun. 2021 ($0.58Mil).

Aerpio Pharmaceuticals's annual other current assets declined from Dec. 2018 ($1.37 Mil) to Dec. 2019 ($1.05 Mil) increased from Dec. 2019 ($1.05 Mil) to Dec. 2020 ($2.11 Mil).


Aerpio Pharmaceuticals Other Current Assets Historical Data

The historical data trend for Aerpio Pharmaceuticals's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerpio Pharmaceuticals Other Current Assets Chart

Aerpio Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Other Current Assets
Get a 7-Day Free Trial 0.56 0.64 1.37 1.05 2.11

Aerpio Pharmaceuticals Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 2.30 2.11 1.99 0.58

Aerpio Pharmaceuticals Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Aerpio Pharmaceuticals Other Current Assets Related Terms

Thank you for viewing the detailed overview of Aerpio Pharmaceuticals's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
9987 Carver Road, Cincinnati, OH, USA, 45242
Aerpio Pharmaceuticals Inc is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The company's product razuprotafib is a small molecule Tie2 activator being developed for the topical ocular treatment of primary open-angle glaucoma. Other products under the pipeline are ARP-1536 and AKB-4924.
Executives
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Pravin Dugel director C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Cheryl Cohen director C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Steven Prelack director 7 WHEELWRIGHT ROAD, MEDFIELD MA 02052
Regina Marek officer: Vice President of Finance C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, SUITE 420, CINCINNATI OH 45242
Joseph H. Gardner director, officer: President C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, CINCINNATI OH 45242
Kevin G. Peters officer: See Remarks C/O AERPIO PHARMACEUTICALS, INC., 9987 CARVER ROAD, C OH 45242
Muneer A Satter director, 10 percent owner C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Chau Quang Khuong director, 10 percent owner C/O ORBIMED ADVISORS, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Michael W Rogers officer: See Remarks C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Stephen J Hoffman director, officer: Chief Executive Officer C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Novartis Bioventures Ltd 10 percent owner C/O NOVARTIS INTERNATIONAL AG, WSJ-200.220, CH-4002 BASEL V8 0000000000
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056

Aerpio Pharmaceuticals (Aerpio Pharmaceuticals) Headlines

From GuruFocus